Strategic Partnerships Opportunities to collaborate with academic medical centers and cancer programs for clinical validation and early access pilots around RESOLVE. Leverage recent ASCO data presentations to engage oncology leadership and procurement teams, and pursue joint studies and real-world evidence to demonstrate value in diagnostic pathways.

Targeted Markets Focus on symptomatic patients and high-risk groups, including obesity-related cancer risk highlighted in CORE-HH data. Engage pulmonology, thoracic oncology, primary care, and cancer screening programs to integrate RESOLVE into triage workflows, with emphasis on reducing diagnostic uncertainty and streamlining referrals.

Implementation Readiness Prepare deployment-ready solutions and analytics integrations to fit lab networks and hospital IT ecosystems. Emphasize compatibility with existing workflows, LIMS, and EHRs, and build pilot programs with reference labs for scalable rollout.

Funding Momentum Leverage sustained funding momentum to accelerate field teams, manufacturing, and payer discussions. Target large health systems, IDNs, and payer organizations with a compelling value case for earlier detection and potential cost savings in diagnostic pathways, backed by clinical data.

Differentiated Value Position RESOLVE as a new category bridging suspicion and diagnosis with a multi-cancer approach enabled by cfDNA methylation analytics. Highlight the unmet need in the uncertainty window and the advantage over single-cancer tests to drive pilot commitments and broader adoption.